Male Breast Cancer: Epidemiology, Diagnosis, Molecular Mechanisms, Therapeutics, and Future Prospective
Oncology Research · 2026 · 34 (1) · 1-10
DOI: 10.32604/or.2025.068238 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Oncology Research, 2026. Verfasst von Ashok Kumar Sah und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Laboratory Sciences, College of Applied & Health Sciences, A Sharqiyah University, Ibra, 400, Oman. Hauptthemen laut MEDLINE: Breast Neoplasms, Male. Die Arbeit wurde bisher 5-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Male breast cancer (MBC) is rare, representing 0.5%-1% of all breast cancers, but its incidence is increasing due to improved diagnostics and awareness. MBC typically presents in older men, is human epidermal growth factor receptor 2 (HER2)-negative and estrogen receptor (ER)-positive, and lacks routine screening, leading to delayed diagnosis and advanced disease. Major risk factors include hormonal imbalance, radiation exposure, obesity, alcohol use, and Breast Cancer Gene 1 and 2 (BRCA1/2) mutations. Clinically, it may resemble gynecomastia but usually appears as a unilateral, painless mass or nipple discharge. Advances in imaging and liquid biopsy have enhanced early detection. Molecular mechanisms involve hormonal signaling, HER2/epidermal growth factor receptor (EGFR) pathways, tumor suppressor gene alterations, and epigenetic changes. While standard treatments mirror those for female breast cancer, emerging options such as cyclin-dependent kinase 4 and 6 (CDK4/6), and poly(ADP-ribose) polymerase (PARP) inhibitors, immunotherapy, and precision medicine are reshaping management. Incorporating artificial intelligence, molecular profiling, and male-specific clinical trials is essential to improve outcomes and bridge current diagnostic and therapeutic gaps.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Laboratory Sciences, College of Applied & Health Sciences, A Sharqiyah University, Ibra, 400, Oman.
- School of Allied Health Sciences, Sanskaram University, Jhajjar, 124108, Haryana, India.
- Department of Psychiatry, Medical Psychology and Narcology, Samarkand State Medical University, Samarqand, 140100, Republic of Uzbekistan.
- Department of Folk Medicine and Professional Diseases, Bukhara State Medical Institute, Bukhara, 200118, Republic of Uzbekistan.
- Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Jouf University, Sakaka, 72388, Saudi Arabia.
- Department of Pharmaceutical Chemistry, University of Hafar Al Batin, Hafar Al Batin, 31991, Saudi Arabia.
Zitieren
APA
Sah, A. K., Choudhary, R. K., Sabrievna, V. A., Dzhuraevich, K. I., Abbas, A. M., Shalabi, M. G., Siddique, N. A., Alshammari, R. R., Trivedi, N., & Elshaikh, R. H. (2026). Male Breast Cancer: Epidemiology, Diagnosis, Molecular Mechanisms, Therapeutics, and Future Prospective. Oncology Research, 34(1), 1-10. https://doi.org/10.32604/or.2025.068238
Vancouver
Sah AK, Choudhary RK, Sabrievna VA, Dzhuraevich KI, Abbas AM, Shalabi MG, et al. Male Breast Cancer: Epidemiology, Diagnosis, Molecular Mechanisms, Therapeutics, and Future Prospective. Oncology Research. 2026;34(1):1-10. doi:10.32604/or.2025.068238
BibTeX
@article{Sah2026,
author = {Sah, Ashok Kumar and Choudhary, Ranjay Kumar and Sabrievna, Velilyaeva Alie and Dzhuraevich, Karomatov Inomdzhon and Abbas, Anass M and Shalabi, Manar G and Siddique, Nadeem Ahmad and Alshammari, Raji Rubayyi and Trivedi, Navjyot and Elshaikh, Rabab H},
title = {Male Breast Cancer: Epidemiology, Diagnosis, Molecular Mechanisms, Therapeutics, and Future Prospective},
journal = {Oncology Research},
year = {2026},
volume = {34},
number = {1},
pages = {1--10},
doi = {10.32604/or.2025.068238}
}
EUVIMED